Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- 3 Top-Ranked Consumer ETFs to Buy Now
- RTI: When is the Fed's "Taper Telegraph" Coming?
- Top Stocks with Big Potential Catch-Up Moves
- Roundtable Top Picks of the Week
- Anatomy of Success: Green Mountain Coffee
- The Mega-Rally Rolls On
- RTI: Prediction Contest: S&P 500 on Dec. 31st
- Biotechnology ETF Investing 101
- 3 Dividend Stocks at Reasonable Prices
- AWS 5/21: The Beginning of the End for QE
- PFP 5/21: Below the Surface
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/21/2013
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| FEDERAL MOGU | FDML | 7.00% |
| SUMMER INFAN | SUMR | 6.93% |
| NATUS MEDICA | BABY | 5.38% |
| NEW ORIENTAL | EDU | 5.34% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Alnylam Pharmaceuticals, Inc. ( ALNY - Analyst Report ) and Monsanto Company ( MON - Analyst Report ) recently formed a strategic alliance to implement biological technologies in the field of agriculture. As per the alliance, Alnylam’s broad RNAi-based (ribo nucleic acid interference) intellectual property (IP) and proprietary technologies along with Monsanto’s new BioDirect technology will help deliver innovative biological solutions to farmers.
The Agreement
As per the terms of the agreement, Monsanto, a leading global provider of technology-based solutions and agricultural products, will acquire worldwide, exclusive rights to use Alnylam’s technologies in the field of agriculture. Monsanto will be able to grant sub-licenses as well.
Alnylam will receive $29.2 million in upfront payments, along with milestone payments and other additional funding from Monsanto. The agreement also allows Alnylam to receive royalty payments on the products that will utilize the company’s platform technology and IP. With this alliance, Monsanto becomes Alnylam’s strategic partner in agriculture for the next 10 years.
Our Take
We are pleased to see Alnylam stepping beyond its primary focus area. This will promote broader use of the company’s technology. Alnylam had earlier entered into key partnerships with companies like Medtronic, Inc. ( MDT - Analyst Report ) , Novartis AG ( NVS - Snapshot Report ) , Biogen Idec Inc. ( BIIB - Analyst Report ) , Roche Holding AG ( RHHBY ) , Takeda Pharmaceutical Company Limited ( TKPYY ) and Cubist Pharmaceuticals Inc. ( CBST - Analyst Report ) to share its RNAi know-how.
The Monsanto alliance will fetch upfront, milestone payments and other additional funding that will strengthen the company’s cash position. Alnylam exited the second quarter of 2012 with cash, cash equivalents and total marketable securities of around $293 million.
Besides these agreements, Alnylam makes use of its potentially revolutionary RNAi technology for the treatment of a wide array of diseases. The company expects to have five such RNAi therapeutic programs in advanced clinical development by the end of 2015. We expect investor focus to remain on the company’s pipeline going forward.
The stock carries a Zacks #3 Rank (Hold rating) in the short run.
Read the full Analyst Report on MON
Read the full Analyst Report on ALNY
Read the full on RHHBY
Read the full Analyst Report on MDT
Read the full Analyst Report on CBST
Read the full Snapshot Report on NVS
Read the full Analyst Report on BIIB
Read the full on TKPYY